Welcome to AMYPAD!

We are a collaborative research initiative aiming to improve the understanding, diagnosis and management of Alzheimer’s disease through the utilisation of ß-amyloid PET imaging.

The Amyloid imaging to prevent Alzheimer’s disease (AMYPAD) initiative aims to:

 

→ About Us

 

→ Our papers

 

Homepage Image Neuraceq™ (left) and Vizamyl™ (right). Upper images: amyloid negative scans. Lower images: amyloid positive scans.
Latest News
New paper on the impact of cerebral blood flow and amyloid load on SUVR bias
New paper on the impact of cerebral blood flow and amyloid load on SUVR bias 12 May 2022 A new paper has recently been published in the journal EJNMMI Research......
AMYPAD announces end of recruitment in the Prognostic and Natural History Study
AMYPAD announces end of recruitment in the Prognostic and Natural History Study 11 May 2022 On the 30th of April the recruitment was formally ended and the study succeeded in recruiting 1320 participants......
The Neuronet Coordination and Support Action releases updated Decision Tool for engagement with Regulatory and Health Technology Assessment bodies
The Neuronet Coordination and Support Action releases updated Decision Tool for engagement with Regulatory and Health Technology Assessment bodies 09 May 2022 Neuronet is pleased to announce the launch of an updated version of their Decision Tool to support engagement with Regulatory and HTA bodies......
Recruitment status (as 29 April 2022)
Recruitment status (as 29 April 2022)